mRNA-based therapeutics pioneer innovation in the biopharmaceutical industry

BioNTech, Novo Nordisk and Pfizer are among the leaders in this innovative field of therapy, according to Business perspectives of cell and gene therapynative edition Scientific board.

BioNTech and Crescendo Biologics

BioNTech is a biotechnology company based in Mainz, Germany, with platforms focused on mRNA therapy, cell engineering, antibodies and low molecular weight immunomodulators. In addition to the company’s collaboration with Pfizer on the COVID-19 vaccine, BioNTech is focusing much of its efforts precisely on developing cancer treatments using advanced technology as immunotherapy.

In support of this effort, BioNTech is collaborating with Crescendo Biologics to develop accurate immunotherapies against cancer in addition to other undiscovered diseases. As part of this collaboration, Crescendo will receive $ 40 million in advance, as well as payments for development, regulatory and commercial phases that could potentially reach $ 750 million.

In turn, Crescendo will promote its Humabody heavy chain variable domain platform to deliver human mRNA-based antibody domains and engineered cellular therapies designed for BioNTech’s purposes.

Additional financial details of this cooperation are not disclosed.

Novo Nordisk and 2seventy bio

Novo Nordisk is a leading global healthcare company headquartered in Denmark, which develops treatments for serious chronic diseases including diabetes, obesity, endocrine disorders and other serious chronic diseases. In addition, the company is developing treatments for rare blood diseases such as hemophilia A.

To further use hemophilia A treatment options, Novo Nordisk has entered into a licensing agreement with 2seventy bio for research and development of an in vivo gene editing method. Under this agreement, Novo Nordisk will use megaTAL technology based on 2seventy bio mRNA to develop treatments using this new therapeutic approach. This collaboration represents a significant shift in the use of mRNA-based therapeutic agents.

2seventy bio will receive an advance payment of $ 5 million in addition to payments of up to $ 35 million soon and options. 2seventy resume will also be eligible for additional payments and fees.

Additional financial details of the cooperation are not disclosed.

Pfizer and Codex DNA

Pfizer is a leading biopharmaceutical research company offering treatments for a variety of ailments ranging from cardiovascular disease to common pediatric diseases. As a partner in developing a leading COVID-19 mRNA-based vaccine with BioNTech, Pfizer continues to work with other companies to build on its innovation. One such collaboration includes the Pfizer partnership and a licensing agreement with Codex DNA.

Through an agreement with Codex, Pfizer will gain access to and further develop the new Codex DNA Enzymatic DNA Synthesis (EDS) technology for potential use for existing Pfizer mRNA-based vaccines and other biopharmaceutical products. Codex DNA EDS technology is a scalable and cost-effective approach to research designed to reduce the time required to build synthetic DNA, RNA and protein.

In partnership with Pfizer, Codex technology can be used to more effectively and efficiently research and develop mRNA-based vaccines such as the COVID-19 vaccine. The financial details of the cooperation are not disclosed.

As unprecedented diseases, such as COVID-19, continue to emerge, new technologies are needed to develop vaccines and treatments. The widespread use of mRNA technology in COVID-19 vaccines clearly demonstrates this point.

Companies such as BioNTech, Novo Nordisk and Pfizer have recognized this growing need and are expanding such technologies by collaborating and partnering with other healthcare companies. As more companies follow their example with their own innovations and partnerships, the healthcare sector is more likely to defeat new diseases along with existing ones.

To stay up to date with the latest business developments in the cell and gene therapy industry, check out Business perspectives of cell and gene therapy today!

Related reading

Copyright © 2022


Leave a Comment